Versamune is the company’s new investigational MUC1-targeted immunotherapy candidate. The therapy is intended for individuals who have failed prior treatments. PDS submitted the application to the US regulator
This initiative is stated to be a part of the company’s Phase I contract development and manufacturing organisation (CDMO) growth strategy. In response to the growing need for
The collaboration aims to explore this WEE1 kinase inhibitor for treating human papillomavirus + (HPV+) and HPV- HNSCC with specific genomic markers. As per the agreement, Aprea will
This approval marks the first availability of the therapy in this region. The partnership between Vivus and its marketing partner PharmaAccess aims to equip healthcare providers in the
The approval is intended for those who have a minimum of one F508del mutation or another responsive CFTR gene mutation. The company is working with the National Institute for Health and
Despite a non-binding letter of intent signed in November last year, the companies have mutually decided to discontinue negotiations after failing to meet critical conditions within the set
This investment is part of the company’s plan to broaden its Peptide Platform business and exceed €1bn in sales by 2028. CordenPharma has finalised plans for a new
The move is said to propel the company’s antibody discovery and engineering offerings, and is in line with its current growth plan. Previously known as Distributed Bio, the
This approval covers all indications of the reference products and the biosimilars are anticipated to be available by June 2025 in the country as per the settlement agreement
The oral Factor B inhibitor of the alternative complement pathway is designed for this rare kidney condition with no approved treatments, which significantly impacts young individuals’ lives. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.